On 27 May 2024, Fresenius Kabi announced that its BLA for denosumab has been accepted for review by the US FDA as biosimilar to Amgen’s Prolia®. The biosimilar is to be indicated for osteoporosis in men and women, including glucocorticoid-induced osteoporosis, and bone loss due to prostate or breast cancer.
Sandoz’s Wyost® and Jubbonti® were the first denosumab biosimilars approved in the US in March 2024. Following the April 2024 resolution of US BPCI litigation, commenced by Amgen against Sandoz in May 2023, Jubbonti® and Wyost® are expected to launch in the US from 31 May 2025.
On 28 May 2024, Amgen commenced BPCIA litigation against Celltrion in the United States District Court for the District of New Jersey, alleging infringement of 29 patents relating to denosumab. Celltrion applied to the FDA for marketing authorisation of its denosumab biosimilar, CT-P41, in December 2023.